| Literature DB >> 16478647 |
Michiaki Ishii1, Masaki Iwai, Yoshinori Harada, Tsunao Kishida, Hidetsugu Asada, Masaharu Shin-Ya, Yoshito Itoh, Jiro Imanishi, Takeshi Okanoue, Osam Mazda.
Abstract
Metastatic liver tumors are highly malignant and refractory to conventional therapies. TRAIL-resistant CT-26 cells underwent apoptosis in vitro in the presence of both recombinant TRAIL (rTRAIL) and a suboptimal dose of actinomycin D (ACD). Co-administration of soluble TRAIL (sTRAIL) gene and ACD suppressed the metastatic liver tumors of CT-26, significantly inducing apoptosis in the tumors, while such effects were not demonstrated in mice that received either the sTRAIL gene or ACD alone. The gene therapy of sTRAIL with a suboptimal dose of an anticancer drug is a new strategy for treatment of multiple liver metastasis.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16478647 DOI： 10.1016/j.canlet.2005.12.040
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679